New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 7, 2014
06:09 EDTAUXL, QLTIAxial enters voting agreement with Auxilium over QLT Inc.
Axial Capital disclosed that it entered into a voting agreement with Auxilium Pharmaceuticals (AUXL) agreeing to vote in favor of any transactions requiring shareholder vote arising out of a plan of merger entered into among QLT Inc. (QLTI) and Auxilium. Axial added that it has been and may continue to be in contact with members of QLT's management, board and others regarding alternatives that the company could employ to maximize shareholder value. Axial owns 17.35% of QLT's outstanding shares.
News For QLTI;AUXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
08:35 EDTAUXLBioSpecifics announces new data on XIAFLEX for Peyronie's Disease
Subscribe for More Information
November 20, 2014
07:09 EDTAUXLAuxilium presents STENDRA data at SMSNA meeting
Auxilium Pharmaceuticals announced that data were presented regarding the use of STENDRA tablets for the treatment of erectile dysfunction at the 20th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America held in Miami from November 20-23. A post-hoc analysis of data from a placebo-controlled, Phase 4 study of STENDRA evaluated men who had at least one attempt at intercourse within approximately 15 minutes of taking the medication. The STENDRA 100 and 200mg doses demonstrated statistically significant improvement in onset of erectogenic effect at approximately 15 minutes compared to placebo, with a mean per-patient proportion of sexual attempts that resulted in at least one successful intercourse within approximately 15 minutes after dosing of 73.3% and 71.5%, respectively. Results of a study examining the proportion of men with ED who reported successful intercourse within the first three doses of STENDRA showed more than 60% of patients reported successful intercourse within the first three doses of STENDRA. This compares to about 40% with placebo. A higher percentage, or 75% for STENDRA vs. 56% for placebo, also reported success after any dose.
07:07 EDTAUXLAuxilium presents XIAFLEX for Peyronie's Disease data
Auxilium Pharmaceuticals announced presentations of data from new studies, as well as new analyses of data from the Phase 2 and the pivotal Phase 3 IMPRESS trials evaluating XIAFLEX for the treatment of Peyronie's disease, at the 20th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America held in Miami from November 20-23. Data were presented providing further evidence that PD bother is clinically significant and may be a useful measure in clinical practice when treating PD. Data were also presented suggesting that improvements in PD bother are correlated with improvements in penile curvature deformity.
November 19, 2014
07:33 EDTAUXLEndo, Auxilium receive early termination of HSR waiting period for deal
Subscribe for More Information
November 18, 2014
07:02 EDTAUXLAntares Pharma names James Fickenscher as SVP, CFO
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use